Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04313634 |
Recruitment Status :
Recruiting
First Posted : March 18, 2020
Last Update Posted : July 21, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy | Drug: Dasatinib Drug: Quercetin Drug: Fisetin | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 120 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: A Phase 2, Single-Center, 20-week, Open-Label, Randomized Controlled Trial. |
Actual Study Start Date : | June 9, 2020 |
Estimated Primary Completion Date : | April 30, 2022 |
Estimated Study Completion Date : | March 31, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Dasatinib plus Quercetin Treatment Goup
Subjects will receive Dasatinib (D; 100 mg for two days) plus Quercetin (Q; 1000 mg total daily for three consecutive days taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
|
Drug: Dasatinib
Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated
Other Name: Sprycel Drug: Quercetin Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg |
Experimental: Fisetin Treatment Group
Subjects will receive Fisetin (F; ~20 mg/kg/day for three consecutive days) taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
|
Drug: Fisetin
Fisetin will be supplied in 100 mg capsules to be administered orally |
No Intervention: Untreated Control Group
Subjects will not receive any intervention
|
- Percent Changes in C-terminal telopeptide of type I collagen [CTX] [ Time Frame: Baseline, 20 weeks ]Percent changes in serum bone turnover markers C-terminal telopeptide of type I collagen [CTX]
- Percent Changes in amino-terminal propeptide of type I collagen [P1NP] [ Time Frame: Baseline, 20 weeks ]Percent changes in serum bone turnover markers amino-terminal propeptide of type I collagen [P1NP]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 70 Years and older (Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Able and willing to provide informed consent.
- Normal postmenopausal women
- Aged ≥70 years
Exclusion Criteria:
- Hemoglobin A1c ≥8.0%
- Abnormal screening labs (see below)
- Presence of significant liver or kidney disease
- Presence of heart failure
- Malignancy (including myeloma)
- Malabsorption, including gastric bypass / reduction, Crohn's disease
- Subjects who are diabetic and on insulin, sulfonylureas or SGLT2 inhibitors. Diabetes alone or Metformin use are not grounds for exclusion.
- Hyperthyroidism
- Acromegaly
- Cushing's syndrome
- Hypopituitarism
- Subjects with a fracture within the past six months
-
Undergoing treatment with any medications that affect bone turnover, including the following:
- adrenocorticosteroids (> 3 months at any time or > 10 days within the previous yr), anticonvulsant therapy (within the previous year),
- calcium supplementation of > 1200 mg/d (within the preceding 3 months),
- bisphosphonates (within the past 3 yrs),
- denosumab,
- estrogen (E) therapy or treatment with a selective E receptor modulator, or teriparatide (within the past yr)
- β-blockers
- QTc >450 msec
- Inability to provide consent
- Inability to tolerate oral medication
- eGFR<30 ml/min/1.73 m2
- Subjects on therapeutic doses of anti-coagulants (e.g. warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc)
- Subjects with hypovitaminosis D (25-hydroxyvitamin D [25(OH)D] <20 ng/ml, whose level does not improve above 20 ng/ml after two courses of 8-week treatment of 1000 IU/d of Vitamin D. They will be referred to their primary provider should this occur.
- Subjects taking anti-arrhythmic medications known to cause QTc prolongation
- Subjects taking potentially senolytic agents within the last 6 months: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax
- Subjects currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy
- Subjects taking H2 antagonists
- Tyrosine kinase inhibitor therapy
- Subjects not having a PBTL p16INK4a mRNA expression level >95 percentile of young female controls (this cut-off is depicted by the dotted line in Fig. 6)
- Known hypersensitivity or allergy to Dasatinib, Quercetin, or Fisetin
- Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Rifampin
- Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of Fisetin: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, warfarin, heparin, full dose ASA, clopidogrel, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron, riluzole,
- Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus or sirolimus). If antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic.
- Subjects taking strong inhibitors of CYP3A4
- Subjects on antiplatelet agents (Clopidogrel [Plavix]; Dipyridamole + Asprin [Aggrenox]; Ticagrelor [Brilinta]; Prasugrel [Effient]; Ticlopidine [Ticlid] or Other) who are unable or unwilling to reduce or hold therapy prior to and during the study drug dosing periods. Subjects may continue their previous regimen between study drug dosing periods.
- Subjects on quinolone antibiotic therapy for treatment or for prevention of infections within ten days.
- Subjects taking proton pump inhibitors and unwilling to discontinue therapy for two days before and during the study drug dosing periods.
- Subjects with clinically evident fluid retention
- Subjects with evidence of right heart strain on ECG
- Subjects with a history of pulmonary hypertension
- Subjects with an abnormal Complete Blood Count (clinically insignificant changes would be acceptable based on the judgement of the investigators)
- Presence of any condition the Investigator believes would place the subject at risk or would preclude the subject from successfully completing all aspects of the trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04313634
Contact: Tammie Volkman, RN | 507-538-6023 | volkman.tammie@mayo.edu | |
Contact: Joshua Farr, PhD | farr.joshua@mayo.edu |
United States, Minnesota | |
Mayo Clinic in Rochester | Recruiting |
Rochester, Minnesota, United States, 55905 |
Principal Investigator: | Sundeep Khosla, MD | Mayo Clinic |
Responsible Party: | Sundeep Khosla, M.D., Principal Investigator, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT04313634 |
Other Study ID Numbers: |
18-010546 |
First Posted: | March 18, 2020 Key Record Dates |
Last Update Posted: | July 21, 2020 |
Last Verified: | July 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Dasatinib Quercetin Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Antioxidants Protective Agents Physiological Effects of Drugs |